Patient experience of symptoms and impacts of COVID-19: a qualitative investigation with symptomatic outpatients
- PMID: 35501077
- PMCID: PMC9062460
- DOI: 10.1136/bmjopen-2021-055989
Patient experience of symptoms and impacts of COVID-19: a qualitative investigation with symptomatic outpatients
Abstract
Objectives: There is little in-depth qualitative evidence of how symptoms manifest themselves in outpatients with COVID-19 and how these in turn impact outpatients' daily lives. The objective of the study was therefore to explore the experience of outpatients with COVID-19 qualitatively, concerning the symptomatic experience and its subsequent impact on daily life.
Setting: Qualitative research study comprising virtual in-depth, open-ended interviews with outpatients and clinicians.
Participants: Thirty US adult patients with COVID-19 were interviewed within 21 days of diagnosis. Patients were 60% female and 87% white, who had to self-report one of the following: fever, cough, shortness of breath/difficulty breathing, change/loss of taste/smell, vomiting/diarrhoea or body/muscle aches. Five independent clinicians were also interviewed about their experience treating outpatients.
Primary and secondary outcome measures: Transcripts were analysed thematically to organise symptoms and impacts of daily life into higher-order overarching categories, and subsequently propose a conceptual model. The adequacy of the sample size was assessed by conceptual saturation analysis.
Results: Patient-reported concepts were organised into six symptom themes (upper respiratory, lower respiratory, systemic, gastrointestinal, smell and taste, and other) and seven impact themes (activities of daily living, broad daily activities, leisure/social activities, and physical, emotional, professional and quarantine-specific impacts). Symptom type, severity, duration and time of onset varied by patient. Clinicians endorsed all patient-reported symptoms.
Conclusions: The manifestation of symptoms in outpatients is heterogeneous and affects all aspects of daily life. Outpatients offered new detailed insights into their symptomatic experiences, including heterogeneous experiences of smell and taste, and the impacts that symptoms had on their daily lives. Findings of this research may be used to supplement existing knowledge of the outpatient experience of mild-to-moderate COVID-19, to further inform treatment guidelines and to provide an evidence base for evaluating potential treatment benefits.
Keywords: COVID-19; INFECTIOUS DISEASES; QUALITATIVE RESEARCH; VIROLOGY.
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: DR is a Regeneron Pharmaceuticals employee/stockholder and former Roche employee, and current stockholder. SS and VM are Regeneron Pharmaceuticals employees/stockholders. AJP has received consulting fees from Regeneron Pharmaceuticals, honoraria from NACE (CME), and has participated in an advisory board for Boehringer Ingelheim. NM, AR and KP are employees of Modus Outcomes. PM is the cofounder and CEO of Modus Outcomes. NM, AR, KP and PM consulted for Regeneron Pharmaceuticals.
Figures

Similar articles
-
Thematic analysis to explore patients' experiences with long COVID-19: a conceptual model of symptoms and impacts on daily lives.BMJ Open. 2024 Jan 17;14(1):e076992. doi: 10.1136/bmjopen-2023-076992. BMJ Open. 2024. PMID: 38233059 Free PMC article. Review.
-
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0. Trials. 2021. PMID: 33810796 Free PMC article.
-
Understanding the Patient Experience of Severe, Recurrent, Bilateral Nasal Polyps: A Qualitative Interview Study in the United States and Germany.Value Health. 2020 May;23(5):632-641. doi: 10.1016/j.jval.2019.11.005. Epub 2020 Mar 11. Value Health. 2020. PMID: 32389229
-
Qualitative interviews to improve patient-reported outcome measures in late-onset Pompe disease: the patient perspective.Orphanet J Rare Dis. 2021 Oct 12;16(1):428. doi: 10.1186/s13023-021-02067-x. Orphanet J Rare Dis. 2021. PMID: 34641935 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2021 Feb 23;2(2):CD013665. doi: 10.1002/14651858.CD013665.pub2. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 20;5:CD013665. doi: 10.1002/14651858.CD013665.pub3. PMID: 33620086 Free PMC article. Updated.
Cited by
-
Living and Coping with Olfactory and Taste Disorders: A Qualitative Study of People with Long-COVID-19.Healthcare (Basel). 2024 Mar 30;12(7):754. doi: 10.3390/healthcare12070754. Healthcare (Basel). 2024. PMID: 38610176 Free PMC article.
-
Improving Health and Well-Being of People With Post-COVID-19 Consequences in South Africa: Situation Analysis and Pilot Intervention Design.JMIR Form Res. 2025 Apr 10;9:e58436. doi: 10.2196/58436. JMIR Form Res. 2025. PMID: 40209024 Free PMC article.
-
Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles.Sci Rep. 2023 Aug 7;13(1):12784. doi: 10.1038/s41598-023-39681-7. Sci Rep. 2023. PMID: 37550377 Free PMC article. Clinical Trial.
-
The symptoms evolution of long COVID‑19 (SE-LC19): a new patient-reported content valid instrument.J Patient Rep Outcomes. 2024 Aug 9;8(1):87. doi: 10.1186/s41687-024-00737-5. J Patient Rep Outcomes. 2024. PMID: 39117891 Free PMC article.
-
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.Infect Dis Ther. 2023 Sep;12(9):2269-2287. doi: 10.1007/s40121-023-00861-7. Epub 2023 Sep 26. Infect Dis Ther. 2023. PMID: 37751015 Free PMC article.
References
-
- Centers for Disease Control and Prevention . Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19), 2021. Available: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-manageme...
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical